title: Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission.
authors.forename: Hulya
authors.initials: H
authors.lastname: Ozsahin
authors.forename: Joël
authors.initials: J
authors.lastname: Fluss
authors.forename: Valerie
authors.initials: V
authors.lastname: McLin
authors.forename: Pierre
authors.initials: P
authors.lastname: Wacker
authors.forename: Raymond
authors.initials: R
authors.lastname: Miralbell
authors.forename: Claudine
authors.initials: C
authors.lastname: Helg
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D014182:Transplantation, Autologous
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007376:Interleukin-2; D000069283:Rituximab